Communiqués Orion Oyj Nasdaq Helsinki

Actions

ORNAV

FI0009014369

Produits pharmaceutiques

Temps réel estimé Cboe Europe 10:04:05 21/09/2026			Varia. 5j.	Varia. 1 janv.
81,35 ^EUR	-0,06%		+2,90%	+29,07%

17/09	Sources : Orion180 fixerait son prix d'introduction en dessous de la fourchette initiale - BN (R)	FW
17/09	Sources : Orion180 fixerait son prix d'introduction en dessous de la fourchette initiale - BN	FW

Communiqués

18/09	Orion Corporation: Acquisition of own shares during week 38, 2026	GL
11/09	Orion Corporation: Acquisition of own shares during week 37, 2026	GL
04/09	Orion Corporation: Acquisition of own shares during week 36, 2026	GL
04/09	102,000 Orion Corporation A shares converted into B shares	GL
27/08	Orion Corporation to commence acquisition of own shares for its share-based incentive plans	GL
10/08	Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint	GL
17/07	Orion Oyj : Half-Year Financial Report 2026	PU
17/07	Orion Group Half-Year Financial Report January–June 2026	GL
17/07	Orion Corporation’s financial reporting and Annual General Meeting in 2027	GL
15/07	45,611 Orion Corporation A shares converted into B shares	GL
06/07	Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026	AQ
03/07	Orion Oyj : publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026	PU
03/07	Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026	GL
30/06	Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market	GL
23/06	Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission	GL
18/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
17/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
16/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
15/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
11/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
10/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
05/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
01/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
30/05	Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours	GL
21/05	Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting	GL